The rate of grade 3 AREs within 2 years was only 8.7%, and concurrent systemic therapy did not increase AREs ( P = 0.08), indicating promising efficacy and safety for PULSAR, both alone and combined with systemic therapy (95).Given the favorable early intracranial response with PULSAR (the primary Triple Threat regimen achieved a median volume reduction of 38.1% by the final adaptive session for the 24 cm lesion group (95)), coupled with literature suggesting that short-term tumor shrinkage 20% after SRT predicts excellent local control (96), and the need to reduce toxicity in patients with extended survival, Dohopolski, M.s team designed the Phase I trial NCT07139990
Despite increasing epidemiologic evidence linking lipid metabolism to CS-induced emphysema (Lundstrm et al., 2011
Mechanistic Cause: Muscle loss is largely driven by caloric restriction and lack of mechanical stimulus, not a direct toxic effect of the drug on muscle fibers
Sustained Weight Loss & Blood Sugar Balance Helps regulate glucose levels, reducing the risk of cravings and energy crashes
The copper peptide your shelf serums cant match
